|
|
- 2018
替格瑞洛与氯吡格雷对急性ST段抬高型心肌梗死行介入治疗患者安全性及有效性评估的回顾性分析
|
Abstract:
摘要 目的:探讨急性ST段抬高心肌梗死(STEMI)患者行直接经皮冠状动脉成形术(PCI)前应用新型抗血小板聚集药物替格瑞洛与氯吡格雷对梗死相关血管疗效及预后的影响.方法: 采用回顾性研究,总共收集了290个进行PCI术的STEMI患者.患者分为两组,其中替格瑞洛组97例,氯毗格雷组193例.对两组患者入院的基线资料,包括年龄、性别、危险因素;首次入院实验室检查;冠脉病变数量;冠脉血流分级及7 d内出血事件等进行比较分析.结果: 通过冠状动脉造影发现病变血管数目及位置,两组间未见明显差异.负荷剂量的氯吡格雷组或替格瑞洛组,主要出血事件及次要出血事件在7 d内均无统计学差异.术后TIMI血流分级替格瑞洛组有高于氯吡格雷组趋势,具有统计学差异(P=0.013).结论: 本回顾性研究初步得出替格瑞洛比氯吡格雷能提升患者PCI术后冠脉血流,减少术中无复流的发生.
| [1] | LI J, LI X, WANG Q, et al.ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data[J]. Lancet, 2015, 385(9966): 441-451. |
| [2] | NIJJER S S, PETRACO R, VAN DE HOEF T P, et al. Change in coronary blood flow after percutaneous coronary intervention in relation to baseline lesion physiology: results of the JUSTIFY-PCI study[J]. Circulation Cardiovascular Interventions, 2015, 8(6): e001715. |
| [3] | PORTO I, BURZOTTA F, PARMA A, et al.Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-ThrombosIs MultIcentre STudy[OPTIMIST])[J]. The American Journal of Cardiology, 2010, 105(12): 1710-1715. |
| [4] | SCHULZ C, SCHOMIG A, KASTRATI A.Acute coronary artery stent thrombosis following rapid renewal of functional platelets: implications for intensified antiplatelet therapy[J]. Thromb Haemost, 2006, 96(3): 384-386. |
| [5] | KOUL S, ANDELL P, MARTINSSON A, et al.A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI[J]. BMC cardiovascular disorders, 2014, 14: 189. |
| [6] | ALEXOPOULOS D, XANTHOPOULOU I, GOUDEVENOS J.Effects of P2Y12 receptor inhibition in patients with ST-segment elevation myocardial infarction[J]. The American journal of cardiology, 2014, 113(12): 2064-2069. |
| [7] | STEBLOVNIK K, BLINC A, MIJOVSKI M B, et al.Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study[J]. Circulation, 2016, 134(25): 2128-2130. |
| [8] | SAMOS M, FEDOR M, KOVAR F, et al.Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?[J]. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis, 2016, 27(2): 117-120. |
| [9] | GUKATHASAN N, MEHRAN R.Acute coronary syndromes: advances in antithrombotics[J]. Curr Atheroscler Rep, 2013, 15(4): 318. |
| [10] | SUN J, XIANG Q, LI C, et al.Efficacy and safety of novel oral P2Y12 receptor inhibitors in ST-segment elevation myocardial infarction patients undergoing PCI: A systematic review and meta-analysis[J]. J Cardiovasc Pharmacol, 2017, 69(4): 215-227. |
| [11] | ALEXOPOULOS D, KONTOPRIAS K, GKIZAS V, et al.Ticagrelor vs clopidogrel followed by ticagrelor re-loading in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, pharmacodynamic comparison[J]. Platelets, 2016, 27(5): 420-426. |
| [12] | FURUTA T, IWAKI T, UMEMURA K.Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes[J]. British journal of clinical pharmacology, 2010, 70(3): 383-392. |
| [13] | PREOBRAZHENSKII D V.Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study[J]. Kardiologiia, 2010, 50(1): 68. |
| [14] | GRECH E D, RAMSDALE D R.Acute coronary syndrome: ST segment elevation myocardial infarction[J]. BMJ, 2003, 326(7403):1379-1381. |
| [15] | ROSENSTEIN R S, PARRA D.Ticagrelor versus clopidogrel in acute coronary syndromes[J]. N Engl J Med, 2009, 361(24): 2385-2386. |
| [16] | KOMOCSI A, ARADI D, KEHL D, et al.Meta-analysis of randomized trials on access site selection for percutaneous coronary intervention in ST-segment elevation myocardial infarction[J]. Arch Med Sci, 2014, 10(2): 203-212. |
| [17] | KIKKERT W J, VAN GELOVEN N, VAN DER LAAN M H, et al. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications[J]. Journal of the American College of Cardiology, 2014, 63(18): 1866-1875. |
| [18] | ARIZA-SOLE A, FORMIGA F, BERNAL E, et al.Prognosis of elderly ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention[J]. Am Heart J, 2014, 168(1): e3. |
| [19] | ANGIOLILLO D J, BASS T A.Percutaneous coronary interventions in ST-segment-elevation myocardial infarction: shifting paradigms and future perspectives[J]. Circ Cardiovasc Interv, 2013, 6(6): 593-595. |
| [20] | BOZZI L M, MITCHELL B D, LEWIS J P, et al.The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin[J]. Current vascular pharmacology, 2016, 14(1): 116-124. |
